Clinical trials
Myeloma clinical trials
Below are recruiting myeloma clinical trials, each written for real people, not researchers. We’re tracking 570 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07448779Recruiting
A study on N-glycosylation and its role in AL amyloidosis
This research study looks at how certain sugar molecules (N-glycosylation) on proteins may play a role in a disease called AL amyloidosis. Researchers will study blood samples from people with related plasma cell disorders to learn more about these sugars, which could help with diagnosis and treatment.
Pavia, PVAges 18–99 - NCT07440290RecruitingPhase 2/Phase 3
Dabrafenib and trametinib for BRAF V600 cancers
This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.
BelfastAges 1 year+ - NCT07413809RecruitingPhase 3
Preventing nausea after stem cell transplant: olanzapine vs dexamethasone
This trial compares two anti-nausea drug regimens (one with olanzapine, one with dexamethasone) to prevent delayed nausea and vomiting after a stem cell transplant for multiple myeloma. It aims to find which is better at controlling these side effects.
Ningbo, ZhejiangAges 18–65 - NCT07410494RecruitingPhase 1/Phase 2
Personalized donor cell therapy for advanced solid tumors
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
Beijing, Beijing MunicipalityAges 8–85 - NCT06821880Recruiting
Tracking infections and quality of life in blood cancer patients
This study uses a smartphone or web app to track infections and quality of life in people with multiple myeloma or chronic lymphocytic leukemia who have a weakened immune system. The goal is to create a better screening tool for infections and understand how the disease and treatment affect daily life.
Innsbruck, TyroliaAges 18 years+ - NCT07403630Recruiting
Tumor chemogenomic profiler for cancer patients of all ages
This trial uses a new testing platform to analyze the genes and proteins in your tumor, aiming to find the most effective treatments for people with cancer that has come back, is not responding to treatment, or has spread. It is designed for both children and adults with any type of blood cancer or solid tumor.
Palermo, PalermoAges 1 year+ - NCT07390071Recruiting
Remote rehab program for CAR-T cell therapy patients
This trial tests a home-based rehabilitation program using phone or video sessions to help people with lymphoma or myeloma recover better after CAR-T cell therapy. It aims to improve physical function and quality of life during treatment.
Salt Lake City, UtahAges 21 years+ - NCT07341867RecruitingPhase 1
Dose changes for cancer treatment in people with Duffy null
This trial tests if changing the dose of certain chemotherapy drugs can help people with a genetic trait called Duffy null avoid side effects like low white blood cell counts. It is for people with multiple myeloma or triple-negative breast cancer starting specific treatments.
Boston, MassachusettsAges 18 years+ - NCT07309497Recruiting
Geriatric Assessment for Older Adults Before CAR-T or Bispecific Therapy
This trial studies how a simple geriatric assessment (a check-up for older adults) can help predict side effects and outcomes in patients aged 65+ who are about to receive CAR-T cell therapy or bispecific antibody treatment.
BernAges 65 years+ - NCT06874530Recruiting
Isatuximab for multiple myeloma with 1q21 abnormality
This trial tests if adding the drug isatuximab to standard treatments helps people whose multiple myeloma has returned or stopped responding, especially if their cancer cells have an extra copy of a certain gene (1q21). The study checks how well these drugs work together.
BolognaAges 18 years+ - NCT06028087Recruiting
Blood Clot Prevention Study in Myeloma Patients
This study looks at how blood thinners are used in people with newly diagnosed multiple myeloma. The goal is to find better ways to prevent blood clots during treatment.
RomaAges 18 years+ - NCT07305337Recruiting
AI health education for blood cancer patients
This trial tests if an artificial intelligence (AI) program can help people with blood cancer learn about their condition and treatment. The goal is to see if AI-assisted education improves their understanding and care.
Wuhan, HubeiAges 18–90 - NCT06879379RecruitingPhase 2/Phase 3
KPD Consolidation After Stem Cell Transplant for Newly Diagnosed Myeloma
This trial tests a new way to treat multiple myeloma after a stem cell transplant. It uses a combination of drugs (KPD) to help keep the disease from coming back.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07290309Recruiting
Remote exercise program for cancer survivors
This study tests a remote guided exercise program for cancer survivors to see if it helps with recovery and well-being. It is designed for people who have finished their main cancer treatments and are not already exercising a lot.
Fort Collins, ColoradoAges 18 years+ - NCT07292272Recruiting
Slowing Aging in Blood Cancer Survivors
This study tests a program to help people who have survived a blood cancer stay healthier as they age. It involves exercise and check-ups to see if we can slow down some effects of aging.
Omaha, NebraskaAges 50 years+ - NCT07285044RecruitingPhase 2
Home cancer treatment program for Florida panhandle residents
This study tests whether people with certain cancers can safely receive their regular intravenous treatments at home instead of coming to the clinic. It aims to make treatment more convenient and improve satisfaction, especially for those living in the Florida Panhandle.
Jacksonville, FloridaAges 18 years+ - NCT04513639RecruitingPhase 2/Phase 3
Checking treatment for multiple myeloma after MRD becomes negative
This study looks at whether people with newly diagnosed multiple myeloma can safely continue or adjust treatment after they reach “MRD-negative,” meaning very low signs of disease in the bone marrow. It may help reduce the chance of relapse while avoiding unnecessary treatment for some patients.
ÅlesundAges 18–75 - NCT03711110Recruiting
Heart-protection plan for older people with certain cancers
This trial looks at strategies to help prevent heart and blood-vessel problems in people over 65 who have certain cancers. It may help by monitoring and treating heart risks early to lower the chance of future cardiovascular events.
Santiago de Compostela, A CoruñaAges 65 years+ - NCT07270263Recruiting
Lower-dose blood thinners for people with blood cancers
This trial compares lower doses of two common blood thinner pills (apixaban and rivaroxaban) to a daily injection (enoxaparin) to prevent blood clots in people receiving treatment for blood cancers like multiple myeloma, lymphoma, or certain other blood cancers.
Gdansk, Pomeranian VoivodeshipAges 18 years+ - NCT07268846Recruiting
Prebiotic supplement before colorectal cancer surgery
This trial tests if taking a postbiotic supplement before surgery for colorectal cancer can improve recovery. It may help patients with adenocarcinoma of the large intestine prepare for their operation.
São Paulo, São PauloAges 18 years+ - NCT07249528Recruiting
Using voice recordings to monitor side effects during CAR T-cell therapy
This study tests if daily voice recordings on a smartphone can help detect side effects early in people receiving CAR T-cell therapy for non-Hodgkin lymphoma or multiple myeloma. You will make short voice recordings twice a day and have daily neurological checks.
Basking Ridge, New JerseyAges 18 years+ - NCT07239323RecruitingPhase 1
CAR-T therapy for blood cancers that have returned or not responded
This trial tests a new CAR-T cell therapy for people with certain blood cancers (B-cell acute lymphoblastic leukemia, B-cell lymphoma, or multiple myeloma) that have come back or stopped responding to treatment. The therapy uses your own immune cells, modified in a lab to attack cancer cells, then given back to you intravenously.
Kunming, YunnanAges 18 years+ - NCT07236021Recruiting
e-Motion: emotion support for chronic cancer patients
This trial tests an online program called e-Motion that helps people with chronic cancer manage their emotions. It may help you feel more in control and better cope with your diagnosis and treatment.
Brussels, AnderlechtAges 18 years+ - NCT07226934Recruiting
AI-generated question list for blood cancer patients
This trial tests if an AI tool can help you create a personalized list of questions about your cancer treatment to ask your doctor at your next visit. It is for patients with lymphoma or multiple myeloma who get regular infusion therapy.
St Louis, MissouriAges 18–99
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myeloma?
- Yes. Clin2 currently lists 570 recruiting myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.